Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study
NCT01495897
Basal Ganglia Diseases, Brain Diseases
Paris, France
View Trial DetailsNCT Number: NCT04836715
The objective is to determine the prevalence of visual dysfunction in People with Parkinson's Disease (PwP). The investigators will administer the: Visual Impairment in Parkinson's Disease Screen and Revised-Self-Report Assessment of Functional Visual Performance. Patients seen at Fixel Institute and their caregivers will be invited to participate. Responses to the 2 questionnaires will help determine prevalence rates of visual dysfunction in PwP compared to those both with and without other neurological conditions.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
UF Health Rehab - Fixel Institute, Gainesville, Florida, United States
The purpose of this study is to identify the prevalence of visual dysfunction among Persons with Parkinson's Disease, compared to other neurological conditions and controls without neurological conditions.
Data will be collected anonymously via RedCap. Patients seen at the Fixel Institute that have consented to be contacted regarding research opportunities will be recruited via blast email and advertisement in our Institute's monthly newsletter, the Movement Messenger. The email and newsletter will contain a link for participation in surveys within RedCap so the surveys can be completed anonymously at home. Participation will be completely voluntary and responses will be recorded anonymously. Data will include responses to the following: screening questions, the VIPDQ (Visual Impairment in PD Questionnaire), and the R-SRAFVP (Revised-Self-Report Assessment of Functional Visual Performance).
The investigators will calculate the prevalence of visual impairment (from the VIPDQ) and dysfunction in performance of daily activities (from the R-SRAFVP) for PwP and compare this to the prevalence occurring in other neurological populations as well as the population without any neurological conditions. Other data are collected so the investigators can then evaluate potential confounds or covariates. To ensure statistical methods are accurate, a statistician will be consulted.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 day
Determined from VIPDQ: (with the highest and lowest scores on the VIPD-Q Score). Answers are given on a 4-point Likert scale ranging from "never have problems" to "daily problems"
Time frame: 1 day
Determined from R-SRA FVP: SRAFVP %
Time frame: 1 day
Correlation Coefficient: VIPDQ score and SRAFVP % will be analyzed statistically to report correlation coefficient
University of Florida
Other
Prevalence of Visual Dysfunction in Persons With Parkinson's Disease and Other Neurological Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01495897
Basal Ganglia Diseases, Brain Diseases
Paris, France
View Trial DetailsNCT03675282
Basal Ganglia Diseases, Brain Diseases
New York, United States
View Trial DetailsNCT04847011
Arthritis, Arthritis, Rheumatoid
Kassel, Hesse, Germany
View Trial DetailsNCT04361955
Basal Ganglia Diseases, Brain Diseases
Cleveland, Ohio, United States
View Trial Details